Pod Insights Pharmacy Podcast Network Navigating the Digital Era and Beyond for Engaging Key Decision Makers in Specialty Pharmacy | NASP Specialty Pharmacy Podcast About this episode In this episode of the NASP Podcast, Sheila Arquette, President & CEO of NASP, speaks with Bridgette Kanz Schroader, PharmD, MPA, BCOP, Associate Director within the Medical Affairs Strategy & Publications team at Market Access & Healthcare Consulting, part of Cencora, and Laurie Fazio, Head, Manufacturer Strategy, at FormularyDecisions. They explore the changing landscape of digital communication between biopharma companies and healthcare decision makers (HCDMs) and delve into 3 key topics that are crucial for effective engagement in the digital era with key decision makers: research on how HCDMs are utilizing digital resources and valuable insights into their preferences, how biopharma companies are adapting to meet the evolving needs of HCDMs in a post-pandemic peak era, and innovative strategies to optimize digital communications and the implications for stakeholder relationships.
Transcript 0:05 Speaker 00 You are listening to the global network of podcasters dedicated to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
0:26 Speaker 01 You are listening to the NASP Podcast. This specialty pharmacy podcast is a collaboration with the National Association of Specialty Pharmacy and the Pharmacy Podcast Network. The mission of the National Association of Specialty Pharmacy is to improve specialty pharmacy practice by promoting continuing professional education and certification of specialty pharmacists while advocating for public policies that ensure patient access to specialty medications. As the healthcare industry's leading podcast dedicated to the pharmacy profession, the Pharmacy Podcast Network is proud to bring our listeners the NASP Podcast in collaboration with the National Association of Specialty Pharmacy.
1:08 Speaker 02 Hello, my name is Sheila Arquette and I am the President and CEO of the National Association of Specialty Pharmacy. I am delighted to welcome two very special guests, Dr. Bridgette Cans Schroeder and Lori Fazio. Bridgette Cans Schroeder, PharmD, MPA, Bcop, is an Associate Director within the Medical Affairs Strategy and Publications Team at Market Access and Healthcare Consulting, part of Sancora. In this role, she leads a team focused on medical affairs initiatives, including medical information dissemination, planning and execution, strategic support, and content development. Additionally, she collaborates on global health economics and outcomes research activities,
1:50 Speaker 02 including protocol development and review, and provision of clinical context for real-world evidence generation activities, health economics and outcomes research, roadmapping, and content development of Academy of Managed Care Pharmacy formulary dossiers, global value dossiers, advisory board training slide decks, and scientific publications. Before joining Sancora, Dr. Schroeder was a clinical pharmacy specialist at the Markey Cancer Center at the University of Kentucky in Lexington. She serves as a medical oncology clinical specialist in their ambulatory clinic and as a preceptor to students, residents, and medical fellows. Her research and publication
2:32 Speaker 02 interests focus on immunotherapy and checkpoint inhibition. Dr. Schroeder received her Doctor of Pharmacy and Master of Public Health Administration degrees in 2014 from the University of Kentucky. She completed two years of residency at Vanderbilt University Medical Center in Nashville, Tennessee. She has been a board-certified oncology pharmacist since 2017. Lori Fazio is Head Manufacturer Strategy at Formulary Decisions. Lori leads their business development team in developing and executing sales strategies and tactics to enhance the formulary decisions business. She collaborates with manufacturer subscribers to ensure formulary decisions meets and continues to evolve with their payer engagement
3:16 Speaker 02 and data insights needs. Prior to the acquisition of Formulary Decisions by Sencora, formerly AmerisourceBergen, Lori led the Market Access Technologies team, including the Custom Software Solutions Group at DiMaxium since 2000. Her experience began at a large health benefit consulting firm. She subsequently joined a PBM where she helped employers and insurance companies manage complex and diverse healthcare formulary issues. Lori later joined a large biopharmaceutical manufacturer where she spearheaded their strategies to enhance the company's presence and image within the private sector. She is a frequent speaker at payer and manufacturer conferences and webinars. Her understanding of both the market access environment, unmet
4:01 Speaker 02 needs of manufacturers and payers, and the application of state-of-the-art technologies ensures customers achieve their key business objectives. Lori is a graduate of Western University with a Bachelor of Science in Mathematics and Statistics. Focused on actuarial science. Bridgette and Lori, thanks so much for joining me today.
4:23 Speaker 03 Thank you for having us.
4:24 Speaker 02 So let's start with what are the key components of an effective digital engagement strategy for biopharma companies in the pharmaceutical industry? And why is that important?
4:35 Speaker 04 This means not having only a one point in time engagement that might be tied around a significant milestone such as product approval, but one that builds over time and ensures that there's a continuum of communication digitally. And when we think of a strong digital engagement strategy, it really is one that gets involved with healthcare decision maker customers early and often throughout the commercialization process so that you are ensuring that your customers have the information they need to make informed formulary placement decisions to ultimately get the right treatments to patients in a timely manner.
5:18 Speaker 04 And when I think of biopharma companies and their timeline, it can really be broken down into three main components. Pre-approval, approval and launch, I'll put those two together, and then post-approval. And our experience has shown that healthcare decision makers need different information at each of these time periods. And it's really important that biopharma companies are reaching them with what they need when they need it. In fact, as a best practice, we share the importance of curating your audience early so that a biopharma subscriber can sustain engagement and keep healthcare decision makers informed throughout the product's lifecycle by continuing to raise awareness of the latest
6:03 Speaker 04 and greatest information.
6:06 Speaker 03 Yeah, Lori, that's exactly it. And I think, you know, before we get much further, Lori and I have also been asked by our legal team to make sure that our listeners know they should do their own research in making decisions related to the content we're discussing today. So I promised them I'd say that, so now I have. And so, building on that, I want to go into a little more detail about what Lori was mentioning around that pre-approval, approval and post-approval phases. And really, that pre-approval time period occurs up to two years prior to launch. And what we focus on during that time period is building engagement to ensure that healthcare decision makers are aware of where to go to obtain, you know, the latest information on the product as well as the disease state.
6:50 Speaker 03 So we're really building a product story at that time. And this can include a wide variety of topics like the patient journey, burden of illness, disease state. But for the most part, our pre-approval stage really focuses on the unmet needs and highlighting that in a population of interest. And I, you know, want to call out for our listeners here at NASP, this could be as simple as explaining that like a product is an oral formulation and a biopharma company expects that it'll be distributed through a specialty pharmacy. So that's something that would be really important to know and valuable to know upfront for planning purposes.
7:27 Speaker 03 And really then, as we move into the product approval phase, it's important for our healthcare decision makers to receive support with different resources like payer value propositions, prior authorization forms, formulary kits, all these resources that help communicate that key product information to support actual formulary decision making now that the product's approved. And then, of course, in the post-approval stage, that support needs to be continued. So that could be in the form of additional value demonstration, like using health economics and outcomes research, which we frequently refer to as H U R. It could include cost effectiveness models or retrospective database studies as well as comparative effectiveness research.
8:09 Speaker 04 Yeah, and I think the important point here is that while the information varies over time, it's critical that a biopharma company continue to communicate to that stakeholder audience, particularly because, as we know, therapeutic classes are continually being reevaluated as new products enter the marketplace and/or existing products are seeking new indications. So coming up with a digital engagement strategy that provides this thoughtful roadmap as Bridget outlines ensures that these professionals are receiving the most current information, even when biopharma companies may not be connecting with them daily through live interactions.
8:51 Speaker 02 So what are some examples of like a stakeholder audience? Are we talking about like payers or patients or prescribers? Who are we talking about?
8:58 Speaker 03 You nailed it, Sheila. We're talking about all the above.
9:01 Speaker 02 Okay.
9:02 Speaker 03 And I think that's something that you'll hear Lori and I talk about throughout the podcast is digital engagement and communication in general starts with understanding your audience. So as Lori gets more into formulary decisions and focusing on Syncora's digital platform, the main audience there is going to be payers. But in general, throughout the podcast as well, we'll also be thinking about patients as well as healthcare providers. So really encompassing a diverse group of audiences.
9:34 Speaker 02 Okay, I'm sure the messaging is quite different, right? Even the way the messaging is structured.
9:39 Speaker 03 Absolutely. And you know, one of our big sort of themes that we talk about is meeting the audience where they are. And that that really comes into play, especially in digital engagement. You know, finding our audiences, giving them information where they want to receive it, when they want to receive it, and in their preferred format.
9:58 Speaker 02 Oh, exactly right. There's so much competing for their attention, right? If it doesn't immediately resonate, they're on to something else.
10:03 Speaker 03 Mm hmm. Yep.
10:06 Speaker 02 So how can biopharma companies leverage data analytics to enhance their digital engagement efforts with healthcare providers?
10:14 Speaker 04 I think what's really important here is that it's in the best interest of these biopharma companies to understand if and how their content is being engaged with. Since there's a lot of time and money that's invested into the development of these customer-facing pieces. And when I think of the formulary decisions platform specifically, we're targeted on, as Bridgette mentioned earlier, the payers, your traditional payers, your health plans, your PBMs, but we also have hospitals, IDNs, health systems, public health systems who are using this platform. And so having access to data analytics, such as what types of content have the most activity, or which of these organization types are accessing their, the pieces of content.
11:00 Speaker 04 They're posting, just to name a few, helps a biopharma company better understand what's important and how it might vary depending on the stakeholder audiences we as we mentioned earlier. So for instance, Formula Decisions captures this data to determine the engagement level of each of those resources that has been shared. As posted by our subscribers to the platform. And I think what's really interesting is an analysis that we recently did where we looked at. Everything that biopharma companies have posted in their curated repositories that they have available to them as a subscriber on the platform.
11:37 Speaker 04 Where they can post as much content as varied content as they want over time, obviously subject to their internal review and approval process. But when we looked at that, what was interesting to note was that. What was being accessed most frequently wasn't necessarily what was being posted most frequently. So um product information, for example, which I recognize as a broad category that could include anything from pre-approval information exchange decks to known as pie. To billing and coding guides or pricing overviews and more uh to health economics and outcomes research and real world evidence. Those had the highest activity by our community of healthcare decision makers.
12:22 Speaker 04 Yet clinical trial publications were the most consistently posted resource by our biopharma companies. Um so you you look at that and you simply can't get that information when you send out a file to a customer, right? You're not going to understand how that's being used, if it's being used, where they're going, what they're looking at, how much time they're spending. And I think the analytics really shouldn't just stop at a high level. That should be further broken down by stage, which is what we discussed earlier. That, you know, in pre-approval, at launch, post-approval, what are they looking at? What what are they gravitating to? Because we know that changes over time.
13:03 Speaker 04 And then I think to round that out, you want to get feedback on the product or on the information that you're posting. So that you can ensure that you're reaching your customers where they are with the information they need, when they need it. So the goal really should be to obtain the most comprehensive understanding through both activity metrics and insights via feedback. And that's the power of data analytics and should really be table stakes for any digital engagement strategy.
13:35 Speaker 03 Yeah, and I think, you know, what you're saying is so important, Lori, because our current market, the resources are continuously constrained, right? Like, I think we're all facing that, no matter what part of the industry you're in. And it's really important that we then take those data analytics and use them. So, you know, Lori is talking about how we can get these analytics from things we've done in the past. And then what I think about next is how does that inform the future? So those data analytics can really be brought into our biopharma company clients and inform their strategic development, help to prioritize where they're going to put their resources, you know, focusing on what kind of engagement
14:17 Speaker 03 their materials are having, when to develop those, and how to post them and where to share them.
14:23 Speaker 04 And when we're talking about preapproval, that, nothing preapproval goes to patients, is that correct?
14:28 Speaker 03 Yes, in the sense that preapproval information exchange is a very highly regulated communication piece. So that is strictly for payers. It's not focused on patients. So that's correct. That doesn't mean that patients don't get some type of information about products. Of course, clinicaltrials.gov, publicly available trial results, things of that nature are certainly available. But when we talk about biopharma customers specifically engaging with PI, that is to the payer audience.
15:05 Speaker 04 That's the really nice thing when I think of our platform is that our audience is an audience that is approved in terms of the criteria that they meet. They are an approved audience to receive preapproval information.
15:20 Speaker 02 Yeah, that's awesome. In what ways can digital engagement improve communication and collaboration between biopharma companies and their stakeholders?
15:30 Speaker 03 Yeah, I can take this one, Sheila. So, you know, digital engagement has really evolved to become bidirectional, and that fosters a much more collaborative environment specifically for us between our biopharma companies and their stakeholders, like the payer audience. And like I mentioned earlier, that one key thing that we emphasize and really talk about continuously and effective communication is meeting our audience where they're at. And I think we can all appreciate that we spend far too much time online, right? As just normal people in our day to day. And I think we forget that so do our healthcare decision makers, because at the end of the day, they're also just normal people. So what we've consistently heard over time is they really want information that's easy
16:11 Speaker 03 to access, and it's early in the product lifecycle. On the other side of the fence, then, our biopharma partners really want to be efficient, and they want to be effective with their content development. So it's important to them to understand what kind of information is valuable, which gets back to that data analytics, and when that information is valuable. But it's also equally important to understand how a healthcare decision maker prefers to receive that information, so that biopharma can make a plan. I think we've, you know, alluded to it a little bit here, but there's compliance and there's regulation to consider in the background of making sure that we're digitally engaging, compliantly, and following regulations. So I think that that digital engagement and having that bidirectional
16:56 Speaker 03 feedback is a really great path that we're going down.
17:00 Speaker 04 And I think that's a good point. Bridget, because by now biopharma companies certainly should recognize that that they need to leverage various channels to meet their stakeholder customers. And digital plays a vital role in that process, but it's not the only role. And a best practice really is to have a strong coordination of effort between the feet on the street, their field teams who are going out and talking to their payer customers, and digital engagement. And then to really leverage those advanced analytics that they receive back through that digital engagement to facilitate field team activation. And what I mean by that
17:40 Speaker 04 is recognizing where their stakeholder customers are engaging with content, but also equally where they may not be engaging with content, and where there's an opportunity for the field team to come in and really educate them. So when I look at that, I think it goes a long way in terms of partnership between biopharma companies and their their customer stakeholders when they receive the feedback that I mentioned earlier, and then they act upon it to provide what their customers are looking for.
18:09 Speaker 03 Yeah, absolutely, Lori. I think one thing that we are more commonly recommending is to have these biopharma companies develop a database of content, right, that can be available for use, tagged to specific audiences with specific audience messaging, again, compliant, in line with regulations. And then they can use that database and update it intentionally to meet the needs of healthcare decision makers. And I think this is a shift that we've seen in the industry over time versus, you know, making one-off pieces for a specific audience, really moving to develop that repository of information that can then be tweaked and changed to meet your audience needs. And I think kind of along those same
18:51 Speaker 03 lines, it's really important that companies create internal standard operating procedures. And these can help provide guidance and really increase the comfort with sharing what's traditionally, you know, live content into digital content, and really making sure that this is consistent and compliant. And this is going to help all of the content creators, you know, so that at each company, they're not asking the same questions every time they're developing and sharing materials. And everyone along the continuum feels just a little bit more comfortable with digital engagement.
19:22 Speaker 02 So what role do online platforms play in shaping the perception of a manufacturer among healthcare professionals?
19:30 Speaker 04 So I think it's an interesting question because we're now talking beyond product, but to the manufacturer themselves. And we think of the pandemic and obviously in the pandemic, we saw a significant shift in terms of all of us and healthcare decision makers included leveraging online resources. And for this stakeholder audience, they were using that as a way to access the information they needed when in person simply was not possible. And then post pandemic, as those of us who work remotely certainly can appreciate, most organizations have shifted from a primarily in-person work environment to one that's hybrid or remote. And when we think about that, and we think about the perception of the manufacturer
20:14 Speaker 04 and meeting them where their customers, where they're at, we think of what the field team is doing and the feedback that they're getting through those live engagements and then leveraging an online platform to validate what that field team is hearing. And in many cases, as subscribers have told me, they use that to monitor the perception of them as a manufacturer overall in terms of that partnership. One of the other things that we think about is that a significant time reviewing digital resources in comparison to non-digital ones has come out as a consistent theme. And there was external research that was done that showed that 80% of
20:59 Speaker 04 healthcare decision makers prefer to access information digitally. So it's important for biopharma companies as a partner to have a footprint in that channel as well.
21:10 Speaker 03 And I want to jump in on that, Lori, because I do think that that data is so important. And building on that, 87% of decision makers also said that they prefer either a combination of traditional and digital communication channels or for there to be more in-person meetings. So we're hearing both, right? Like our healthcare decision makers want to be able to access that information digitally, but they don't want to lose the human touch. And I think that's really key for, you know, our manufacturing. Sure our biopharma partners to hear because it's still really important that they're engaging with these stakeholders in a variety of ways. And I think what that means is our biopharma partners have to have effective engagement in a multi-channel approach.
21:55 Speaker 03 So it allows those decision makers to have the flexibility in how they consume information, where and when it's most applicable for them. And I think digital platforms, like you said, Lori, can really serve as that complement to in-person engagement. It allows the decision makers to go back and revisit content. You know, they've got it at their fingertips. They don't have to reach out, but they still have, you know, contacts at our biopharma companies and they still have relationships. And I think that this really shows that the perception of a manufacturer is important and that manufacturers are willing to evolve with the times, right? Like they're trying to do research to understand what their audiences want and what information they need.
22:36 Speaker 03 And I think they're really willing to try new things. And I think all of those things resonate with our decision makers and impact the perception of the biopharma customer.
22:46 Speaker 04 Yeah, and I think that's why it's important to have that coordination, right, between doing live and doing digitally and ensure that they're sharing the insights more broadly across the organization so that they can continue to enhance that partnership.
23:00 Speaker 03 Absolutely. I think one of the buzzwords I really appreciate right now is a surround sound approach. So making, right, it's kind of cool, making sure, and that's what we're hearing. The decision makers want things in a variety of ways. So we've talked a lot about formulary decisions, which is Syncora's digital platform, and that's more of a closed system. So our users are validated to, again, make sure that that audience is following regulations and we're communicating in a compliant way that our manufacturers don't have to worry about as much. But there are other platforms, right? Like we think about social media platforms that are more professional, Doximity, LinkedIn. These can really also be used to share information or entice healthcare decision makers
23:45 Speaker 03 to either reach out directly to the biopharma company for those more Traditional in-person engagements or on the flip side to be more engaged with formulary decisions. And even more so when we're thinking about more of these open systems, it's really important to have internal alignment on the logistics of how you use these systems and the logistics of the posts and consider different options. So for example, a lot of our biopharma companies struggle with like, are we going to allow comments on social media posts? Because that opens a can of worms of potential information that they have to monitor and they have to respond to. So that's important to consider. And then on the flip side, if you
24:27 Speaker 03 are putting this effort and time and resource into using these other platforms, you have to have some way to measure success. So thinking about, you know, what type of performance indicators are you going to monitor and use to determine what engagement that post has generated?
24:42 Speaker 04 Yeah, absolutely. And online platforms such as ours of formulary decisions, which is Bridget mentioned, is a closed platform only for validated healthcare decision makers, offers the flexibility and then can serve as this consolidated portal where healthcare professionals can conveniently access resources from a wide variety of biopharma companies and products, as well as third-party sources, as opposed to having to navigate to multiple resources. And I, I recognize that biopharma companies also find value in having their own pair of portals, and I definitely support that. I think thinking of multiple channels, having formulary decisions is, is
25:27 Speaker 04 another one to consider because we already know that healthcare decision makers are coming here as a trusted third-party source. And plus, as Bridget mentioned earlier, we verify that they meet the FDA definition of a payer when they register and certainly before they have access to the platform. And then we ensure that they reactivate their access every six months. And this gives confidence to our biopharma company subscribers that they can share information in this platform and know it's reaching the audience that meets the compliance needs. And then feedback from our community, our healthcare decision maker community has generally been favorable, with many recognizing that the platform's comprehensive approach to information sharing,
26:12 Speaker 04 it creates a
26:15 Speaker 04 A multifaceted approach for them to have so many resources available. And I think pharma companies recognize that their participation in this closed, secure platform demonstrates partnership, which goes a long way with their customers and a willingness to meet them where they are.
26:32 Speaker 03 Absolutely. I think that that really ties it back to Sheila's question, right? Like by participating in digital engagements, I think biopharma companies in general are saying they understand, you know, healthcare decision makers are really busy. They have a lot of demands for their time and they want to evolve. They want to provide the data that these decision makers need in an easily accessible format. And they want to make sure that they have their information so they can conduct product reviews, just talk about reimbursement and and make sure that those contracting decisions are done in as time efficient a manner as possible.
27:07 Speaker 02 So do you think did COVID, um, did, did, is this a result of COVID? Did COVID accelerate, right? This, this, um, I guess, need and acceptance of digital engagement?
27:19 Speaker 04 Well, when I think back to when we launched formulary decisions in 2010, there was a recognition on the part of the Academy of Managed Care Pharmacy that the old way of doing things, sharing a dossier by sending out a binder, just really wasn't the way anymore. Um, and so I think that started a change, uh, in terms of how to share information. We've seen an increase engagement over time. I will say it did get, it was accelerated as a result of COVID. But interestingly enough, when we look at just the last five years, so going up to ending in 2023, I think we saw an eightfold increase in engagement and
28:03 Speaker 04 that just continues to grow. So I do agree with you. I think, I think COVID played a role, but I think it was more about accelerating this as opposed to something that was started and and everyone was recognizing there was a need for it and we're only going to continue to evolve, uh, with that.
28:23 Speaker 03 One hundred percent. And I think when we then considered those additional audiences, like our healthcare providers that are seeing patients every day and patients themselves, I think COVID definitely accelerated like their need for digital engagement, right? You know, we've got these sort of exaggerated social platforms now like TikTok, where honestly, doctors are talking to patients on TikTok.
28:47 Speaker 02 Oh, my God.
28:49 Speaker 03 I know, I know. But it's really cool. Like, it provides this just absolutely untapped educational potential. And I think what COVID did was make some biopharma companies really have that reckoning. I think, as Lori said, communicating with payers in a digital way has been coming for a long time. I think where biopharma companies have been able to draw the line is commuting, communicating digitally with providers and patients because they just lose so much control of the communication platform and of the resource. But COVID really forced that conversation to come back to the forefront. And I think we're seeing companies develop standard operating procedures to participate because
29:32 Speaker 03 they just understand that there's such an opportunity to put out, you know, unbranded disease state education. You know, it does not have to be product specific. At the end of the day, we are all patient centric and we're trying to create a better healthcare space. And I think that there's so many opportunities now. So I do think COVID allowed biopharma companies to reprioritize that. And I think in my world, in the meta fair space, we're seeing it in the form of digital opinion leaders, where we used to really only focus on key opinion leaders, which were providers that were influencing a disease space or influencing treatment guidelines. And now we've got to also consider digital opinion leaders. So what are these TikTok docs talking to patients about? And, you
30:16 Speaker 03 know, who's following them? Healthcare providers, patients? There's just such a diversity out there. And I think COVID is allowing us to bring that back to the forefront.
30:26 Speaker 02 Sure. Yeah, I think the push to go green, right? Like probably when, you know, formulary decisions are in 2010 when it, when it went live, right? And I remember like the dossiers and then I remember like the P and T packets as well. And then I've heard, you know, COVID, that all went digital as well. But I remember lugging that around and, you know, printing 30 copies of that. And so, um, so, so, yeah, I think, you know, COVID was the, the accelerator of that, which is a good thing, right? We don't need all of that. So how can biopharma companies ensure that their digital engagement strategies comply with all the industry regulations and guidelines?
31:03 Speaker 04 Well, we know that digital solutions provide this really unique opportunity for rapid, essentially real time sharing of resources and, and generation of insights. And due to the fast moving nature of this process, biopharma companies really need to ensure that their practices still fall in line with the FDA guidance, particularly when thinking about what is appropriate to convey during pre-approval because it is very strict and, and focused. And it's important when we, when we speak of pre-approval, in addition to what they are sharing, to ensure that they have a communication mechanism in place to connect with those
31:46 Speaker 04 healthcare decision makers who have accessed earlier content with updated information once it becomes available because that is a requirement as well.
31:56 Speaker 03 Yeah, and I think, you know, what's really important here when we talk about digital engagement and digital resources, it's, it's that it's not different, right? So we really need to intentionally track these resources, just as you would track engaging face to face with a healthcare decision maker or other audience and, and making sure that we're following all of the guidance that applies there. So reporting adverse events in a timely manner, you know, if product quality issues are reported, making sure that those are, those are reported in a timely manner as well. So it, that's what scared, you know, biopharma companies away in the past because it does take some time and investment upfront to ensure you're set up for success. But again, with a little bit of effort, a little bit of standard operating procedures
32:39 Speaker 03 dropped in there, digital engagement can be done efficiently and compliantly. So. I think an example would be that like making sure information communicated is scientifically sound and presented within the correct context. So, you know, if you're presenting the prevalence of a disease state, you need to present, you know, how that was estimated or how the incidence of an adverse event was derived within an economic model. So making sure that those steps that you would take when you're presenting these resources live, you're taking those steps just a slightly different manner when you're doing these things digitally. And I think ultimately our biopharma companies should exercise oversight, right? Again, work instructions, standard operating procedures, anything that they would have
33:22 Speaker 03 had in place for other communication venues, do it for your digital engagement. And that will make sure that your digital strategies are intentionally compliant, just like any of your other communication strategies.
33:34 Speaker 02 So what are some innovative tools or technologies that biopharma companies can use to enhance their digital engagement? There's so much, right, happening with technology and AI and, you know, what are some of these tools and technologies they should consider?
33:50 Speaker 04 AI was exactly where I was going, Sheila. You know, when we look towards the future and AI emerges as a key player and we all hear about AI and how it's being used in many different ways, good and bad, both for personal and professional purposes. And when I think of us and specifically the formulary decisions platform, we're exploring how we can compliantly integrate AI into our platform. And this would help to facilitate meaningful interactions between both our users, who are healthcare decision makers, and a biopharma company's subscribers. So what does that mean? I don't think we really know yet what role AI might be incorporated to our platform, right?
34:34 Speaker 04 We haven't, we haven't fully thought that through. It could be as simple as, and I say simple because I'm not the one developing it, it could be as simple as benefiting our users to help them synthesize all of the information that's available to them, both what they can collect publicly and is available to them within the platform and biopharma curated content that they can only get through the platform or directly through the manufacturer themselves.
35:02 Speaker 04 Without them needing to pull all of that information together themselves. Said another way, we hope to be the AI that healthcare decision makers are using. And when I think on the flip side, and I think of our biopharma company subscribers, AI might be leveraged in a way to weave those activity metrics and feedback together to quickly identify trends or consistent themes that they may need to address so that it can be done more real time. The beauty of AI is that it can pull so much information together so that individuals can digest it faster. But we don't know yet if, how, or when it will be incorporated, but I will say that we do know we will do so thoughtfully and with compliance in mind, as it always is.
35:47 Speaker 03 Yep, absolutely. And I think, you know, thinking about those innovative tools and technology, the other thing that comes to mind for me in the MettaFairs world is omni-channel engagement. So omni-channel engagement was a buzzword from a couple of years back now, but it's really meant to be, again, a central repository of resources that can easily be tweaked or easily be flexed to meet the needs of different customers, different audiences. And then also, there's meant to be a digital component that brings insights back to make sure that those pieces can be updated or make sure that, you know, performance indicators are captured. And I think that we really haven't realized that dream yet of omni-channel engagement.
36:32 Speaker 03 And I think that's sort of the next frontier for the technology and maybe AI will help us move towards that true omni-channel engagement as well.
36:44 Speaker 02 So what challenges do biopharma companies face when they're implementing digital engagement strategies? And then how do they overcome them?
36:51 Speaker 04 I think the biggest challenge that I've heard as our subscribers want to leverage formulary decisions specifically is how to leverage digital engagement for both the communication of medical information so that traditional requires an unsolicited request, reactive response to a request from one of their customer stakeholders, and more of that promotional marketing information to the same healthcare decision maker customers in a way that compliantly separates them both. So when I think back to the evolution of this platform and the things we've put in place. They need, we recognize that we've kept that separation.
37:36 Speaker 04 And we've, we've gone so far as not only to separate the content, but even the metrics and feedback can be separated based on the role of the user at the biopharma company. And when pharma companies are thinking of creating their own payer portals, I think they need to keep this in mind as well to better understand who's eligible to receive that specific piece of information that they want to share.
38:01 Speaker 03 And I think from my side, the biggest challenge, we've touched on it a few times. It's really, you know, the fear of digital engagement and, and what that means for compliance and what that means for their risk level. And how can our biopharma customers get these tools and resources internally approved with buy-in from their legal, medical, regulatory, promotional committees? And I think what we've seen work in the past is really just having an open dialogue. So talk to your teams, talk internally about the risks of digital engagement and then the mitigation. So certainly, just like with any other type of engagement, there's different levels of risk. And if you have that open dialogue internally,
38:42 Speaker 03 you know, your company can really come to a consensus about what risk they're comfortable with and what mitigation strategies they're comfortable with. And then again, write it down. Have that standard procedure so that people don't have to guess, right? Make sure that everyone within your company is aligned on the execution of digital engagement and how to decrease the risk. And that way, if you, you can capture components that help you, you know, report those adverse events, report quality issues. Make sure you're responding to unsolicited requests for information. So really helping to engage there.
39:16 Speaker 04 Yeah, and that's a really important point, Bridgette, because something that the platform certainly takes into consideration is this whole notion of reporting AEs. And when healthcare decision makers register for the platform, part of that registration process includes agreeing to our general terms of use. And in order to complete their registration, this includes acknowledging that this is not where they should be reporting AEs. In fact, we include a link to where they could report AEs. And then this is reinforced again when these healthcare decision makers want to complete any surveys available to them to help mitigate those risks for biopharma companies.
39:57 Speaker 02 So what best practices can biopharma companies adopt to ensure that their digital engagement efforts resonate with a diverse HCDMs to optimize market access?
40:09 Speaker 04 When I think about this, I think of it really as a four-stage approach. So to help them develop and execute a plan to maximize engagement with these various stakeholders. So first, they need to ideate on a roadmap, what they want to present and when, taking into account that information needs and gaps that they need to fill, and then is aligned with where their product is at in its lifecycle, because obviously what they're going to present in pre-approval is very different from what they're going to present two, three years post-approval, and taking into account healthcare decision-maker review timelines. And then based on that strategy, they should execute that tactic by providing and presenting
40:54 Speaker 04 the materials accordingly. Obviously, they should be monitoring activity metrics and monitoring feedback along the way on the value of the content that they're providing and where there are additional information needs so that they can continue to refine that information sharing strategy. So that's really the third stage. And then finally, and I think I can't underestimate the importance of this, but they really do need to monitor key performance indicators of success with these engagements, such as what impact did this have on product perceptions and of course ultimately market access and trickling all the way down to patient access to the product.
41:35 Speaker 03 Absolutely, Lori. I agree, and I think, you know, we can really measure how this has gone in formulary decisions, right? So we know that our clients that have these really intentional processes and intentional approaches, they have demonstrated success. They have increased decision-maker engagement with their products, they have more positive ratings of their materials when decision-makers access through the platform, and they also have a larger share of product activity compared to others who are in the same market basket. So, you know, I think that's something that can be a Applied to other types of digital engagement, but it's definitely this approach in particular is something that we can measure on formulary decisions and really see the success.
42:17 Speaker 03 And you know, ultimately, these factors lead to the same goal, which is what we all have. And again, that's to improve the lives of patients. And we in particular do that by helping improve access to safe and effective therapies in a timely manner.
42:34 Speaker 04 So in closing, any thoughts, any thoughts to, you know, what, what 2025 or the future brings?
42:42 Speaker 03 You know, I think this is, I, I think of this as like the start to an important discussion, right? And I think ultimately, Sheila, what I want our listeners to remember is that digital engagement is really important and it certainly is the way of the future. But the second big point is you cannot lose the human touch. And we hear that over and over again. And I think a lot of people hope that digital pen can take over, but it really can't. We still need to have a human involved, whether it's with AI tools, whether it's with, you know, live meetings with our decision makers. Humans are still important.
43:17 Speaker 04 That's a really good point, Bridgette. Because when I think back to when we launched in 2010 and where we're at today, we've come so far. And I know there's so much more to do, but we're always very cognizant of it does not replace that live interaction that you, you need and want with your customer stakeholders. And there is certain information that you absolutely want to deliver in a live environment. I think of some of those models, whether it's cost effectiveness models, budget impact models. You want to deliver those live to present a partnership with your customer stakeholders and to walk them through that process.
43:58 Speaker 04 So I don't think digital replaces live, but it is certainly a, a wonderful compliment to ensure that you're, you're reaching everyone where they want to be.
44:09 Speaker 02 And that's a perfect way to end our podcast. Thank you so much, Bridgette and Lori, for chatting with me and sharing this valuable information. As a reminder, NASP corporate members are invited to be my guest on one complimentary podcast per year. For more information about this or other NASP membership benefits and events, please feel free to reach out to membership@naspnet.org or visit our website at www.naspnet.org. Until next time, have a great day.
Previous Holistic Strategies to Break Up with Chronic SIBO with Jen Yundt Coles | Holistic Pharmacy Podcast Next NCPA 2024 Annual Convention Coverage | Part One Page updated November 15, 2026 · transcript and summary are machine-generated